YOLFTbeta
ExpreS2ion Biotech Holding AB

ExpreS2ion Biotech Holding AB

EXPRS2 · ST · Healthcare / Biotechnology

0.99SEK+0.03 (+3.13%)

Price History

Full chart

Market Stats

Previous Close0.96
Open0.97
Day Range0.914 – 1.00
52-Week Range1.04 – 22.85
Volume152.42K
Market Cap26.01M
P/E (TTM)0.00
Forward P/E24.04
EPS-3.32
Dividend Yield0.00%
Beta2.17
50-Day Avg1.33
200-Day Avg5.45

About

ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company's lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vaccines for Nipah virus, Malaria, and influenza. It also offers GlycoX-S2, a glyco-engineered variants of the ExpreS2 platform to modify glycosylation patterns in expressed proteins. The company has collaboration agreement with University of Oxford for the development of vaccine for malaria. ExpreS2ion Biotech Holding AB (publ) was incorporated in 2015 is based in Helsingborg, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Bent U. Frandsen MSc
  • Employees19
  • HeadquartersRönnowsgatan 8c, Helsingborg, Sweden, 252 25, Sweden
  • Websitehttps://expres2ionbio.com

Leadership

  • Mr. Bent U. Frandsen MScChief Executive Officer
  • Mr. Keith AlexanderChief Financial Officer
  • Dr. Max M. SogaardChief Scientific Officer

Financials

Income Statement

Currency: SEK2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue6.66M6.62M-4.65M9.79M8.87M13.83M5.26M12.23M5.09M7.05M3.01M3.66M
Growth (%)--0.75%--+110.55%-9.46%+55.94%-61.97%+132.63%-58.43%+38.62%-57.26%+21.37%
Cost of Revenue---1.35M2.19M2.75M3.40M6.10M7.51M5.08M3.65M5.68M46.50M
Gross Profit6.66M6.62M-2.80M3.30M7.60M6.12M10.43M-843.00K4.72M5.00K3.40M-2.67M-42.84M
Gross Margin100.00%100.00%-70.87%77.61%68.96%75.42%-16.03%38.59%0.10%48.27%-88.55%-1171.48%
Operating Expense5.98M6.34M6.71M12.46M19.04M24.37M26.73M30.35M53.12M127.61M109.37M65.03M9.98M
Operating Income688.66K279.31K-9.51M-9.16M-11.44M-18.26M-16.30M-31.20M-48.40M-127.61M-105.97M-67.69M-52.82M
Operating Margin10.33%4.22%--196.95%-116.74%-205.86%-117.83%-593.19%-395.59%-2508.97%-1503.05%-2246.76%-1444.35%
EBITDA-5.81M-5.90M-5.91M-7.37M-8.50M-14.29M-15.24M-28.47M-46.38M-124.49M-102.45M-64.34M-51.35M
EBITDA Margin-87.17%-89.14%--158.34%-86.77%-161.19%-110.20%-541.41%-379.09%-2447.78%-1453.23%-2135.41%-1404.24%
Net Income688.66K279.31K-8.44M-8.54M-9.84M-16.82M-16.70M-31.71M-43.92M-118.61M-91.40M-36.04M-38.09M
Net Income Margin10.33%4.22%--183.53%-100.41%-189.69%-120.78%-603.02%-359.04%-2331.99%-1296.47%-1196.08%-1041.43%
R&D-------216.00K9.81M71.32M51.42M26.66M9.98M
R&D as % of Total Revenue-------4.11%80.23%1402.36%729.35%884.70%272.87%
Interest Expense000557.00K461.00K617.00K971.00K3.53M156.00K871.00K501.00K727.00K451.00K
Interest Expense % of Total Revenue0.00%0.00%-11.97%4.71%6.96%7.02%67.18%1.28%17.13%7.11%24.13%12.33%

Balance Sheet

Currency: SEK2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.11M5.48M4.09M24.61M17.23M20.95M18.71M118.86M151.96M137.36M78.69M104.53M65.11M
Total Liabilities2.18M3.13M10.10M11.73M10.50M12.65M19.79M24.31M11.61M34.04M13.33M40.11M29.42M
Total Equity1.93M2.35M-6.01M12.88M6.74M8.30M-1.08M94.55M140.35M103.33M65.36M64.80M35.69M
Cash134.18K156.59K133.06K6.26M1.51M6.25M5.42M106.83M37.11M110.97M57.60M81.54M47.55M
Total Debt66.28K541.15K1.15M5.87M6.40M6.99M7.87M7.16M5.39M1.85M1.71M1.80M2.21M
Net Debt-67.90K384.55K1.02M-386.00K-1.43M-5.33M-3.92M-104.45M-35.19M-109.12M-55.89M-79.74M-45.35M

Cash Flow

Currency: SEK2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-7.02M-8.61M-12.88M-12.69M-18.18M-45.65M-99.61M-100.89M-33.93M-40.90M
Investing Cash Flow-720.00K-206.00K-813.00K-679.00K-1.08M-100.92M105.33M-2.02M21.27M0
Financing Cash Flow14.65M3.98M18.59M12.57M123.38M74.55M61.46M47.84M34.87M10.78M
Capital Expenditure720.00K206.00K813.00K679.00K885.00K715.00K383.00K2.02M870.00K0
Free Cash Flow-7.74M-8.81M-13.69M-13.37M-19.06M-46.36M-100.00M-102.90M-34.80M-40.90M
FCF to OCF110.25%102.39%106.31%105.35%104.87%101.57%100.38%102.00%102.56%100.00%

Earnings

Report DateMar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Aug 20, 2020Nov 19, 2020Feb 25, 2021Mar 31, 2021Jul 28, 2021Nov 15, 2021Feb 24, 2022May 31, 2022Aug 18, 2022Nov 17, 2022Feb 9, 2023May 16, 2023Aug 17, 2023Nov 16, 2023Feb 8, 2024May 16, 2024Aug 15, 2024Nov 14, 2024Feb 6, 2025May 15, 2025Jun 30, 2025Sep 30, 2025Feb 19, 2026May 28, 2026Aug 20, 2026Nov 12, 2026
EPS Estimate---------------------------------------
EPS Actual-0.91-2.16-2.44-2.59-3.25-2.84-4.01-4.77-3.71-2.32-2.22-4.78-3.83-0.25-0.30-0.69-4.47-0.29-0.29-0.42-0.40-0.69-0.77-1.20-0.70-0.63-0.44-0.35-0.250.69-5.34-7.03-4.30-1.35-1.13-2.41-0.97-0.27-
Surprise---------------------------------------
Timing---------------Pre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market--After-hoursAfter-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap26.01M
Enterprise Value-22.13M
Trailing P/E0.00
Forward P/E24.04
Price / Sales1.07
Price / Book0.28
EPS-3.32
Book Value1.76
Revenue (TTM)24.25M
Gross Profit (TTM)20.75M
EBITDA-42.62M
Profit Margin-148.11%
Operating Margin-103.68%
Return on Equity-85.17%
Return on Assets-41.74%
Shares Outstanding23.75M
Shares Float23.26M
Beta2.17
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Oct 30, 20241:40